Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 30

PMID 33916221

Citations 14

Authors

Alice Indini

Olga Nigro

Csongor Gyorgy Lengyel

Michele Ghidini

Angelica Petrillo

Salvatore Lopez

Francesco Raspagliesi

Dario Trapani

Shelize Khakoo

Giorgio Bogani

Affiliations

Soon will be listed here.

Abstract

Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and other targeted agents. The role of immunotherapy in the treatment of platinum-resistant OC remains undefined. The aim of this review is to describe the immunobiology of OC and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration, as well as provide an overview of future drug development strategies.

Citing Articles

Integrative prognostic modeling of ovarian cancer: incorporating genetic, clinical, and immunological markers.

Lin A, Xue F, Pan C, Li L Discov Oncol. 2025; 16(1):115.

PMID: 39900707 PMC: 11790546. DOI: 10.1007/s12672-025-01819-6.

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.

Borella F, Fucina S, Seminara Y, Denti P, Ferraioli D, Bertero L Curr Oncol. 2024; 31(12):8054-8074.

PMID: 39727717 PMC: 11674396. DOI: 10.3390/curroncol31120594.

Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis.

Huang R, Ji F, Huang L, Qin Y, Liang Z, Huang M Front Oncol. 2024; 14:1477105.

PMID: 39624625 PMC: 11609078. DOI: 10.3389/fonc.2024.1477105.

The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.

Tonti N, Golia DAuge T, Cuccu I, De Angelis E, DOria O, Perniola G Int J Mol Sci. 2024; 25(20).

PMID: 39457020 PMC: 11508316. DOI: 10.3390/ijms252011239.

A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers.

Monberg M, Keefe S, Karantza V, Tryfonidis K, Toker S, Mejia J Oncol Ther. 2024; 12(4):701-734.

PMID: 39453600 PMC: 11573950. DOI: 10.1007/s40487-024-00308-0.

References

Boudsocq F, Benaim P, Canitrot Y, Knibiehler M, Ausseil F, Capp J . Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol Pharmacol. 2005; 67(5):1485-92. DOI: 10.1124/mol.104.001776. View

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R . ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2016; 70:111-121. DOI: 10.1016/j.ejca.2016.09.004. View

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5):672-705. DOI: 10.1093/annonc/mdz062. View

Zeller C, Dai W, Steele N, Siddiq A, Walley A, Wilhelm-Benartzi C . Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567-76. DOI: 10.1038/onc.2011.611. View

Hodi F, Butler M, Oble D, Seiden M, Haluska F, Kruse A . Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008; 105(8):3005-10. PMC: 2268575. DOI: 10.1073/pnas.0712237105. View

Wilson M, Pujade-Lauraine E, Aoki D, Mirza M, Lorusso D, Oza A . Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2016; 28(4):727-732. PMC: 6246494. DOI: 10.1093/annonc/mdw663. View

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman D, Xiao N . Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014; 23(12):2965-70. DOI: 10.1158/1055-9965.EPI-14-0654. View

Bogani G, Ricci M, Vitellaro M, Ditto A, Chiappa V, Raspagliesi F . Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome. Int J Gynecol Cancer. 2019; 29(4):705-710. DOI: 10.1136/ijgc-2019-000277. View

10.

Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I . Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7):1080-1087. DOI: 10.1093/annonc/mdz135. View

11.

Strickland K, Howitt B, Shukla S, Rodig S, Ritterhouse L, Liu J . Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016; 7(12):13587-98. PMC: 4924663. DOI: 10.18632/oncotarget.7277. View

12.

Li A, Yi M, Qin S, Chu Q, Luo S, Wu K . Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019; 12(1):98. PMC: 6744711. DOI: 10.1186/s13045-019-0784-8. View

13.

Simsek C, Esin E, Yalcin S . Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience. J Oncol. 2019; 2019:5483791. PMC: 6446118. DOI: 10.1155/2019/5483791. View

14.

Helder-Woolderink J, Blok E, Vasen H, Hollema H, Mourits M, de Bock G . Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer. 2016; 55:65-73. DOI: 10.1016/j.ejca.2015.12.005. View

15.

Ocadlikova D, Lecciso M, Isidori A, Loscocco F, Visani G, Amadori S . Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Front Oncol. 2019; 9:1004. PMC: 6794495. DOI: 10.3389/fonc.2019.01004. View

16.

Fumet J, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E . Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or.... BMC Cancer. 2020; 20(1):748. PMC: 7418426. DOI: 10.1186/s12885-020-07253-x. View

17.

Srivastava A, Han C, Zhao R, Cui T, Dai Y, Mao C . Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proc Natl Acad Sci U S A. 2015; 112(14):4411-6. PMC: 4394248. DOI: 10.1073/pnas.1421365112. View

18.

Liu J, Herold C, Gray K, Penson R, Horowitz N, Konstantinopoulos P . Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 5(12):1731-1738. PMC: 6802049. DOI: 10.1001/jamaoncol.2019.3343. View

19.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

20.

Darb-Esfahani S, Kunze C, Kulbe H, Sehouli J, Wienert S, Lindner J . Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2015; 7(2):1486-99. PMC: 4811475. DOI: 10.18632/oncotarget.6429. View